Mood disorders and psychosis in HIV

doi:10.1017/CBO9780511543586.005

4 - Mood disorders and psychosis in HIV

Published online by Cambridge University Press: 06 August 2009

Andrea Stolar M.D. ,

Glenn Catalano M.D. ,

Sheryl M. Hakala M.D. ,

Robert P. Bright M.D. and

Francisco P. Fernandez M.D.

Edited by

Kenneth Citron ,

Marie Josée Brouillette and

Alexandra Beckett

Show author details

Andrea Stolar M.D.: Affiliation:
Assistant Professor, Department of Psychiatry and Behavioral Medicine, University of South Florida, College of Medicine, FL, Staff Psychiatrist, Women's Program, Bay Pines Veterans Administration Medical Center, Bay Pines, FL, USA
Glenn Catalano M.D.: Affiliation:
Associate Professor, University of South Florida College of Medicine, FL, Medical Director of Psychiatry, Tampa General Hospital, Tampa, FL, USA
Sheryl M. Hakala M.D.: Affiliation:
Child Fellow, Department of Psychiatry and Behavioral Medicine, University of South Florida, College of Medicine, FL, USA
Robert P. Bright M.D.: Affiliation:
Assistant Professor of Psychiatry, University of North Carolina, Attending Psychiatrist, Carolinas HealthCare System, Charlotte, NC, USA
Francisco P. Fernandez M.D.: Affiliation:
Professor and Chairperson, Department of Psychiatry and Behavioral Medicine, University of South Florida, College of Medicine, Tampa, FL, USA
Marie Josée Brouillette: Affiliation:
McGill University, Montréal
Alexandra Beckett: Affiliation:
Harvard University, Massachusetts

Book contents

Get access

Summary

Introduction

Reported rates of depression among people infected with HIV vary. During the course of their disease, up to 85% of HIV-seropositive individuals report some depressive symptoms, and up to 50% experience a major depressive disorder. The variability across studies may be due to small sample size, population characteristics, and evaluation tools. However, in their meta-analysis of published studies, Ciesla and Roberts (2001) found that people with HIV were almost twice as likely as those who are HIV-seronegative to be diagnosed with major depressive disorder, and that depression was equally prevalent in people with both symptomatic and asymptomatic HIV. In their recent analysis of rates of depression and anxiety disorders in people with HIV, Morrison et al. (2002) found a fourfold increase in the risk of current major depressive disorder in HIV-seropositive women compared with an HIV-seronegative group.

The data regarding the prevalence of mania in people with HIV is scant. Although less common than depression, the risk of mania is still thought to be significant, particularly as the disease progresses (Ellen et al., 1999). Mania may be the behavioral manifestation of direct central nervous system (CNS) pathology or toxicity or, if the patient has a family or personal history of bipolar disorder, mania may suggest a primary affective disorder.

The occurrence of psychosis is not too surprising since people with HIV experience marked disturbances in dopamine metabolism (Berger et al., 1994). Early samples found frequencies ranging between less than 0.5% to 15% (Sewell et al. 1994).

Information

Type: Chapter
Information: HIV and Psychiatry
Training and Resource Manual
, pp. 88 - 109

DOI: https://doi.org/10.1017/CBO9780511543586.005 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Akula, S. K., Rege, A. B., Dreisbach, A. W.et al. Valproic acid increases cerebrospinal fluid zidovudine levels in a patient with AIDS. American Journal of Medicine and Science, 313 (1997): 244–6.Google Scholar

Alciati, A., Fusi, A., D'Arminio Monforte, A.et al. New-onset delusions and hallucinations in patients infected with HIV. Journal of Psychiatry and Neuroscience, 26(3) (2001b): 229–34.Google Scholar

Alciati, A., Starace, F., Scaramelli, B.et al. Has there been a decrease in the prevalence of mood disorders in HIV-seropositive individuals since the introduction of combination therapy? European Psychiatry, 16(8) (2001a): 491–6.Google Scholar

Andersson, E., Hansson, I. and Norlin, K.Depression caused by herpes simplex encephalitis. Atypical symptoms were misleading for diagnosis. Lakartidningen, 93 (1996): 1257.Google Scholar

Backonja, M. M.Use of anticonvulsants for treatment of neuropathic pain. Neurology, 59 (5 Suppl. 2) (2002): S14–17.Google Scholar

Berger, J. R., Kumar, M.Kumar, A.et al. Cerebrospinal fluid dopamine in HIV-1 infection. AIDS, 8 (1994): 67–71.Google Scholar

Bottiglieri, T.Folate, vitamin B12, and neuropsychiatric disorders. Nutritional Review, 54 (1996): 382–90.Google Scholar

Breitbart, W. and Strout, D.Delirium in the mentally ill. Clinical Geriatric Medicine 16 (2) (200): 357–72.

Brouillette, M. -J., Chouinard, G. and Lalonde, R.Didanosine-induced mania in HIV infection. American Journal of Psychiatry, 151 (1994): 12.Google Scholar

Busch, K. A.Psychotic states in human immunodeficiency virus illness. Current Opinion in Psychiatry, 2 (1989): 3–6.Google Scholar

Chang, L., Ernst, T., Leonido-Yee, M.et al. Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV-1 dementia. Neurology, 53(4) (1999): 782–9.Google Scholar

Ciesla, J. A. and Roberts, J. E.Meta-analysis of the relationship between HIV-1 infection and risk for depressive disorders. American Journal of Psychiatry, 158 (2001): 725–30.Google Scholar

Cockram, A., Judd, F. K., Mijch, A. and Norman, T.The evaluation of depression in inpatients with HIV disease. Australian and New Zealand Journal of Psychiatry, 33 (1999): 344–52.Google Scholar

Garza, C. L. S., Paoletti-Duarte, S., Garcia-Martin, C. and Gutierrez-Casares, J. R.Efavirenz-induced psychosis. AIDS, 15(14) (2001): 1911–12.Google Scholar

Ronchi, D., Faranca, I., Forti, P.et al. Development of acute psychotic disorders and HIV-1 infection. International Journal of Psychiatry in Medicine, 30 (2000): 173–83.Google Scholar

Dobs, A. S., Dempsey, M. A., Ladenson, P. W. and Polk, B. F.Endocrine disorders in men infected with human immunodeficiency virus. American Journal of Medicine, 84 (1988): 611–16.Google Scholar

Dommisse, J.Subtle vitamin deficiency and psychiatry: a largely unnoticed but devastating relationship? Medical Hypothesis, 34 (1991): 131–40.Google Scholar

Ellen, S. R., Judd, F. K., Mijch, A. M. and Cockram, A.Secondary mania in patients with HIV infection. Australian and New Zealand Journal of Psychiatry, 33(3) (1999): 353–60.Google Scholar

el-Mallakh, R. S.Mania in AIDS: clinical significance and theoretical considerations. International Journal of Psychiatry in Medicine, 21(4) (1991): 383–92.Google Scholar

Evans, D. L., Ten Have, T. R., Douglas, S. D.et al. Association of depression with viral load, CD8 T lymphocytes, and natural killer cells in women with HIV-1 infection. American Journal of Psychiatry, 159 (2002): 1752–9.Google Scholar

Fernandez, F.Neuropsychiatric aspects of human immunodeficiency virus (HIV-1) infection. Current Psychiatry Reports, 4 (2002): 228–31.Google Scholar

Fernandez, F. and Levy, J. K.Psychopharmacology in HIV-1 Spectrum disorders. Psychiatric Clinics of North America, 17 (1994): 135–48.Google Scholar

Gillenwater, D. R. and McDaniel, J. S.Rational psychopharmacology for patients with HIV-1 infection and AIDS. Psychiatric Annals, 31 (2001): 28–34.Google Scholar

Goldberger, E., Clavere, J. L. and Espagno, J.Dosage de lithium intratumoral (glioblastome cerebral). Encephale, 6 (1980): 139–44.Google Scholar

Goodkin, K., Baldewicz, T. T., Wilkie, F. L. and Tyll, M. D.Cognitive-motor impairment and disorder in HIV-1 infection. Psychiatric Annals, 31 (2001): 37–44.Google Scholar

Grant, I. and Atkinson, J. H. Neuropsychiatric aspects of HIV-1 infection and AIDS. In Kaplan and Sadock's Comprehensive Textbook of Psychiatry, 7th edn., Sadock, B. J., and Sadock, V. A., eds. pp. 308–36. Philadelphia, PA: Lippincott Williams and Wilkins, 2000.

Halman, M. H., Bialer, P., Wort, J. L. and Rourke, S. B. HIV-1 Disease/AIDS. In The American Psychiatric Publishing Textbook of Consultation-Liaison Psychiatry: Psychiatry in the Medically Ill, 2nd edn., Wise, M. G., and Rundell, J. R., eds. pp. 807–51. Washington, DC: American Psychiatric Publishing, Inc, 2002.

Halman, M. H., Worth, J. L., Sanders, K. M.et al. Anticonvulsants use in the treatment of manic syndromes in patients with HIV-1 infection. Journal of Neuropsychiatry and Clinical Neurosciences, 5 (1993): 430–4.Google Scholar

Harris, M. J., Jeste, D. V., Gleghorn, A. and Sewell, D. D.New-onset psychosis in HIV-infected patients. Journal of Clinical Psychiatry, 53 (1991): 369–76.Google Scholar

Hugen, P. W., Burger, D. M., Brinkman, K.et al. Carbamazepine–indinavir interaction causes antiretroviral therapy failure. Annals of Pharmacotherapy, 34(4) (2000): 465–70.Google Scholar

Ickovics, J. R., Hamburger, M. E., Vlahov, D.et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-1-seropositive women: longitudinal analysis from the HIV-1 epidemiology research study. Journal of the American Medical Association, 285 (2001): 1466–74.Google Scholar

Jan Wise, M. E.Neuropsychiatric complications of nevirapine treatment. British Medical Journal, 324 (2002): 879.Google Scholar

Jover, F., Cuadrado, J. M., Andreu, L. and Merino, J.Reversible coma caused by risperidone-ritonavir interaction. Clinical Neuropharmacology, 25(5) (2002): 251–3.Google Scholar

Kaplan, H. I., and Sadock, B. J.Mood Disorders, pp. 524–80. Baltimore, MD: Williams and Wilkins, (1998).

Kelly, D. V., Beique, L. C. and Bowme, M. I.Extrapyramidal symptoms with ritonavir/indinavir plus risperidone. Annals of Pharmacotherapy, 36(5) (2002): 827–30.Google Scholar

Lera, G. and Zirulnik, J.Pilot study with clozapine in patients with HIV-associated psychosis and drug-induced parkinsonism. Movement Disorders, 14(1) (1999): 128–31.Google Scholar

Leserman, J.HIV disease progression: depression, stress, and possible mechanisms. Biological Psychiatry, 54(3) (2003): 295–306.Google Scholar

Levin, G. M., Nelson, L. A., DeVane, C. L.et al. A pharmacokinetic drug–drug interaction study of venlafaxine and indinavir. Psychopharmacology Bulletin, 35(2) (2001): 62–71.Google Scholar

Lyketsos, C. G. and Federman, E. B. (1995). Psychiatric disorders and HIV–infection: impact on one another. Epidemiology Review, 17 (1995): 152–64.Google Scholar

Lyketsos, C. G., Schwartz, J., Fishman, M. and Treisman, G.AIDS mania. Journal of Neuropsychiatry and Clinical Neurosciences, 9(2) (1997): 277–9.Google Scholar

Maggi, J. D. and Halman, M. H.The effect of divalproex sodium on viral load: a retrospective review of HIV-1-positive patients with manic syndromes. Canadian Journal of Psychiatry, 46(4) (2001): 359–62.Google Scholar

Maldonado, J. L., Fernandez, F. and Levy, J. K. Acquired immunodeficiency syndrome. In Psychiatric Management of Neurological Disease, Lauterbach, E. C., ed. pp. 271–95. Washington, DC: American Psychiatric Publishing, Inc, 2000.

Markowitz, J. C., Klerman, G. L. and Perry, S.Interpersonal psychotherapy of depressed HIV-seropositive outpatients. Hospital and Community Psychiatry, 43(1992): 885–90.Google Scholar

Martin, L., Tummala, R. and Fernandez, F.Psychiatric management of HIV-1 Infection and AIDS. Psychiatric Annals, 32 (2002): 133–40.Google Scholar

Maxwell, S., Scheftner, W. A., Kessler, H. A. and Busch, K.Manic syndrome associated with zidovudine treatment. Journal of the American Medical Association, 259 (1988): 3406–7.Google Scholar

McDaniel, J. S., Chung, J. Y., Brown, L.et al. Practice guideline for the treatment of patients with HIV-1/AIDS. American Journal of Psychiatry, 157 (2000): 1–61.Google Scholar

Moog, C., Kuntz-Simon, G., Caussin-Schwemling, C. and Obert, G.Sodium valproate, an anticonvulsant drug, stimulates human immunodeficiency virus type 1 replication independently of glutathione levels. Journal of General Virology, 77 (1996): 1993–9.Google Scholar

Morrison, M. F., Petitto, J. M., Ten Have, T.et al. Depressive and anxiety disorders in women with HIV infection. American Journal of Psychiatry, 159 (2002): 789–96.Google Scholar

Murphy, D. A., Greenwell, L. and Hoffman, D. Factors associated with antiretroviral adherenceamong HIV-infected women with children. Abstract X14 International AIDS Conference, 2002.

Navia, B. A., Cho, E. S., Petito, C. K. and Price, R. W.The AIDS dementia complex: II. Neuropathology. Annals of Neurology, 19 (1986): 525–35.Google Scholar

Nemeroff, C. B., DeVane, C. L. and Pollack, B. G.Newer antidepressants and the cytochrome P450 system. American Journal of Psychiatry, 153 (1996): 311–20.Google Scholar

Poulsen, H. D. and Lublin, H. K.Efavirenz-induced psychosis leading to involuntary detention. AIDS, 17(3) (2003): 451–3.Google Scholar

Schaerf, F. W., Miller, R. R., Lipsey, J. R. and McPherson, R. W.ECT for major depression in four patients infected with human immunodeficiency virus. American Journal of Psychiatry, 146(6) (1989): 782–4.Google Scholar

Sewell, D. D., Jeste, D. V., Atkinson, J. H.et al. HIV-associated psychosis: a study of 20 cases. American Journal of Psychiatry, 151 (1994): 237–42.Google Scholar

Simpson, D. M., McArthur, J. C., Olney, R.et al. Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology, 60(9) (2003): 1508–14.Google Scholar

Singh, A. N., Golledge, H. and Catalan, J.Treatment of HIV-related psychotic disorders with risperidone: a series of 21 cases. Journal of Psychosomatic Research, 42(5) (1997): 489–93.Google Scholar

Soldatovic-Stajic, B. and Drezgic-Vukic, S.Case report of a female patient with post-infection depression. Medicinski Pregled, 49 (1996): 57–8.Google Scholar

Starace, F., Bartoli, L., Aloisi, M. S.et al. Cognitive and affective disorders associated to HIV infection in the HAART era: findings from the NeuroICONA study. Acta Psychiatrica Scandinavica, 106(1) (2002): 20–6.Google Scholar

Tanquary, J.Lithium neurotoxicity at therapeutic levels in an AIDS patient. Journal of Nervous and Mental Disease, 181(8) (1993): 518–19.Google Scholar

Trapnell, C. B., Klecker, R. W., Jamis-Dow, C. and Collins, J. M.Glucuronidation of 3'-azido-3'-deoxythimidine (zidovudine) by human liver microsomes: relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid. Antimicrobial Agents and Chemotherapy, 42 (1998): 1592–6.Google Scholar

Tucker, J. S., Burnam, A., Sherbourne, C. D., Kung, F. Y. and Gifford, A. L. (2003). Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. American Journal of Medicine, 114 (2003): 573–80.Google Scholar

Wagner, G. J., Rabkin, J. G. and Rabkin, R.A comparative analysis of standard and alternative antidepressants in the treatment of human immunodeficiency virus patients. Comprehensive Psychiatry, 37 (1996): 402–8.Google Scholar

Whitefield, S. G., Everett, A. S. and Rein, M. F.Neurosyphilis and human immunodeficiency virus infection (letter). Journal of Infectious Diseases, 164 (1991): 609.Google Scholar

Wise, M. G., and Gray, K. F. Delirium, dementia, and amnestic disorders. In The American Psychiatric Press Textbook of Psychiatry, 2nd edn, Hales, R. E., Yudofsky, S. C. and Talbott, J. A., eds. pp. 311–53 Washington, DC: American Psychiatric Publishing, 1994.

Witvrouw, M., Schmit, J. C., Remoortel, B.et al. Cell type-dependent effect of sodium valproate on human immunodeficiency type 1 replication in vitro. AIDS Research and Human Retroviruses, 13 (1997): 187–92.Google Scholar

Accessibility standard: Unknown

Accessibility compliance for the PDF of this book is currently unknown and may be updated in the future.